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ABSTRACT
Over 1.900 colorectal tumors will arise in association with a
hereditary colorectal cancer syndrome in Spain in 2009.
The genetic defects responsible for the most common syndro-
mes have been discovered in recent years.
Genetic testing helps diagnose affected individuals and allows
identification of individuals at-risk.
Colonoscopy and prophylactic colectomy decrease colorectal
cancer incidence and overall mortality in patients with hereditary
colon cancer.
Extracolonic tumors are frequent in these syndromes, so speci-
fic surveillance strategies should be offered.
Key words: Familial adenomatous polyposis. Lynch syndrome.
MYH-associated polyposis. Hereditary colon cancer.
INTRODUCTION
In 2009, it is estimated that around 38,000 people (1)
in Spain will be diagnosed with colorectal cancer (CRC).
Among these cases, more than 15% will exhibit familial
clustering, and over 1,900 tumors (5%) will arise in asso-
ciation with a hereditary colorectal cancer syndrome. The
most common hereditary colon cancer syndromes are:
Familial Adenomatous Polyposis (FAP), attenuated FAP
(AFAP), MYH associated polyposis (MAP), and Lynch
syndrome, also known as Hereditary Non-Polyposis Col-
orectal Cancer syndrome (HNPCC) (2).
During the last two decades, the most important ad-
vancement has been the identification of the genes that
underlie these syndromes. This has permitted more accu-
rate classifications of the various syndromes based upon
genetic criteria, and consequently this has resulted in
more tailored management strategies based on these cri-
teria (3). The management of individuals with hereditary
colon cancer or at-risk for hereditary colon cancer is dra-
matically different, so recognizing these syndromes is
critical. Specifically, surveillance strategies for colon and
extra-colonic tumors as well as surgical approaches (4)
for the prevention and treatment of cancer reflect the
heightened risks.
This review is focused on current treatment strategies
in hereditary colon cancer. It is important to recognize
that “treatment” includes not only management of al-
ready diagnosed cancers but also to prevention of cancer
in these high-risk populations. We first briefly summarize
the major clinical features of each syndrome, including
pattern of inheritance and penetrance, age at diagnosis
and associated extra-colonic tumors.
Familial adenomatous polyposis and attenuated FAP
FAP is the most common adenomatous polyposis syn-
drome. Its prevalence is 1:5.000-10.000, with a uniform
worldwide distribution, affecting both genders equally
(5). Inherited in an autosomal dominant manner with a
virtually penetrance of 100%, it is caused by a germline
mutation in the Adenomatous Polyposis Coli (APC) tu-
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mor suppressor gene on chromosome 5q21 (6). In 15-
20%, the cases are “de novo” without clinical or genetic
evidence of FAP in the parents (7). Recent studies indi-
cate the presence of mosaicism in approximately 15% of
such cases (8,9).
Classic FAP is characterized by the development of
hundreds to thousands of colorectal adenomas starting
during the teenage years. Those polyps will inevitably
progress to colorectal cancer by the age of 40 years. In
addition, multiple gastric fundic gland polyps can devel-
op. Duodenal, peri-ampullary, or ampullary adenomas ul-
timately develop in nearly all FAP patients at a median
age at diagnosis of 38 years (10). Duodenal lesions may
progress over time with an estimated cumulative risk of
duodenal adenocarcinoma of 10% by the age of 60 years
(11), making it the second most common malignancy in
FAP.
Associated extra-intestinal features include desmoids
tumors, congenital hypertrophy of the retinal pigment ep-
ithelium, epidermoid cysts, osteomas and thyroid cancer,
primarily the papillary variant (12). The majority of
desmoids tumors occur within 5 years after abdominal
surgery (13). Of note, desmoids tumors rank as the sec-
ond cause of mortality behind metastatic carcinoma in
FAP patients (14). A family history of desmoids and
germline mutations beyond codon 1444 have been identi-
fied as independent risk factors for desmoids (13,15).
Attenuated FAP is a phenotypically distinct variant of
FAP in which patients present with fewer than 100 ade-
nomas, more proximal colonic locations of polyps, and
an approximate delay of 15 years in the age of CRC on-
set. There are, however, no differences in upper gastroin-
testinal tract lesions. This phenotype has been consistent-
ly linked to APC germline mutations located at the 5’ end
(proximal to codon 157) or the 3’ end of the gene (distal
to codon 1596) (5).
MYH associated polyposis
Mutations in the human MutY homologue (MYH) gene
can also result in multiple colorectal adenomas. The syn-
drome, designated MYH associated polyposis (MAP), is
unique in that it is inherited in an autosomal recessive
manner. TheMYH gene, located on the short arm of chro-
mosome 1, is a DNA glycosylase that participates in the
base excision repair process by correcting mutations
from oxidative damage. The Y165C and G382D mis-
sense mutations account for the majority (80%) of all
MYH mutations in Caucasians (16).
The MAP syndrome is categorized as an oligopolypo-
sis syndrome and phenotypically resembles AFAP with
polyps frequently numbering less than 100. In European
populations, approximately 25% of individuals with
more than 10 adenomatous polyps carried biallelic
germline MYH mutations (16,17). However, there is also
a subset that displays features of classic FAP, as biallelic
mutations in MYH are responsible for up to 7.5% cases
of APC-negative classic FAP (16). Interestingly, these in-
dividuals resemble cases of FAP with “de novo” APC
mutations, as there is no evidence of polyposis in either
parent.
The precise colon cancer risk associated with bi-allelic
MYH mutations has not yet been established, but most evi-
dence points to a high penetrance approaching the 100%
level appreciated in FAP. The mean age at colon cancer di-
agnosis is 50 years (17). The implication of a single MYH-
mutated allele remains unclear, but some evidence suggests
that these individuals are at a modestly increased risk (3-
fold) of colorectal cancer compared with the general popu-
lation (18). Thus far, there is no evidence of a direct causal
relationship with extracolonic tumors, but some features of
FAP including fundic gland polyps and duodenal adenomas
have been reported (16,17,19, 20).
Lynch syndrome
Lynch syndrome is the most common hereditary colon
cancer syndrome and accounts for about 2-3% of all col-
orectal cancer cases (21). Also recognized as HNPCC,
Lynch syndrome is due to mutations in a DNA mismatch
repair (MMR) gene (MLH1, MSH2, MSH6 or PMS2) and
exhibits an autosomal dominant inheritance pattern with
a lifetime risk of colon cancer between 60-80% (22,23).
Due to this genetic alteration, nearly all colorectal tumors
that arise in individuals with Lynch syndrome display a
distinctive molecular signature called microsatellite in-
stability (MSI) (24). MSI testing can serve as a useful
screening test for HNPCC, but it should be recognized
that MSI is also found in up to 15% of sporadic tumors
(24). Because the sensitivity of germline genetic testing
in Lynch syndrome approximates 70%, families who
have MSI-positive tumors and a consistent family history
but no germline mutation can still be considered to have
the Lynch syndrome (25).
Colorectal cancers are diagnosed at an average age of
45 years (26) and are typically located in the proximal
colon (70%) (21). Synchronous and metachronous tu-
mors are commonly seen. Moreover, a particular set of
histopathological features has been associated with these
tumors: mucinous and signet-ring differentiation,
medullary growth pattern, poor differentiation, Crohn’s-
like lymphocytic infiltration and the presence of tumor-
infiltrating lymphocytes.
Many extracolonic tumors have been associated with
Lynch syndrome. The uterus is the most common site out-
side of the colon. In fact, the risk of endometrial cancer
equals or exceeds the risk for colon cancer among women
with Lynch syndrome (22). Other tumors consistently re-
ported in this syndrome are gastric, ovarian, small bowel,
bladder, urinary tract, biliary tract, brain and skin (sebaceous
adenomas or carcinomas and keratoacanthomas) (27).
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GENETICS AND DIAGNOSIS
The management and treatment of hereditary colon
cancer first depends upon the accurate diagnosis of each
syndrome. The most important advance in this aspect has
been the introduction of genetic testing for germline
DNA alterations. In spite of its clinical value, genetic
testing is limited by its cost and concerns regarding pri-
vacy. Patients may be reluctant to be identified as a carri-
er of a cancer-causing genetic mutation that potentially
may limit their ability to obtain insurance or employment
(28). Who to test and for which syndrome to test remain
the key issues.
Genetic testing for hereditary colon cancer analyzes
human DNA from a blood sample in order to detect alter-
ations in a gene known to cause a particular disorder.
This can be accomplished by directly examining the
DNA (sequence analysis and deletion/duplication analy-
sis) or looking at markers co-inherited with a disease-
causing gene (linkage testing).
A positive genetic testing in a symptomatic individual
is considered “diagnostic” and confirms the suspected
genetic disorder. In addition, “predictive” genetic testing
can be offered to asymptomatic individuals with a family
history of hereditary cancer to provide risk assessment. In
general, genetic testing of an affected individual is neces-
sary for testing of any other family members to be inter-
pretable. Once a mutation has been identified in a family,
testing is technically straightforward (3). Genetic coun-
seling is strongly recommended prior to genetic testing
(3).
Classic FAP has striking clinical phenotype. A diagno-
sis can be comfortably made based upon clinical features,
but genetic testing plays a critical role for risk assessment
in asymptomatic family members (3). Individuals with-
out a family history of polyposis -so-called “de-novo”
cases of FAP- who have a nondiagnostic or equivocal
(variant of uncertain significance) result for APC gene
testing should be tested for MYH.
Patients with adenomatous oligopolyposis (between
10-100 adenomas) represent a challenge. This may very
well represent either AFAP or MAP, and differentiating
between these two is important in formulating an appro-
priate management strategy, particularly in terms of fam-
ily counseling, extracolonic tumor surveillance and
chemoprevention (3). A positive germline test can estab-
lish either diagnosis, but in the absence of that informa-
tion other clinicopathological features might be useful. A
family history suggestive of an autosomal dominant in-
heritance will point to AFAP. The absence of fundic
gland polyps and duodenal adenomas in upper GI en-
doscopy will do MAP diagnosis more likely.
The identification of Lynch syndrome is much less
straightforward due to the absence of florid polyposis.
Three lines of information are considered for establishing
the diagnosis: family history, molecular tumor character-
istic (MSI) and germline DNA testing. A family history
indicative of Lynch syndrome is defined by the Amster-
dam criteria (I and II, Table I). It is important to recog-
nize that although a family history of colorectal cancer is
helpful when present, its absence does not exclude Lynch
syndrome. The Bethesda guidelines (Table I) were for-
mulated as a set of less restrictive criteria that indicate
which tumors should be tested for MSI. A discussion of
the different diagnostic algorithms and their rationale
when evaluating possible Lynch syndrome is beyond the
scope of this review and has been recently addressed
(25). The most accurate and confident diagnosis of Lynch
syndrome is made by a positive genetic test result. How-
ever, a positive family history that meets Amsterdam cri-
teria plus tumor analysis showing MSI should also be
considered sufficient for the diagnosis. In contrast, fami-
lies who fulfill Amsterdam criteria but do not have evi-
dence of MSI appear to represent a separate entity. For
the time being, the term “familial colorectal cancer type
X” has been suggested to distinguish them from Lynch
families (29).
Unfortunately, genetic testing is not perfect. For exam-
ple, a “negative” test result can be difficult to interpret. It
is possible that genes other than those currently available
for testing may be involved. Negative results are there-
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Table I. Amsterdam I and II Criteria and Bethesda Guidelines
Amsterdam I criteria
At least three relatives with colorectal cancer:
1. One is a first-degree relative of the other two
2. At least two successive generations should be affected
3. At least one colorectal cancer case diagnosed before age
50 years
4. Familial adenomatous polyposis has been excluded
Amsterdam II criteria
At least three relatives with a hereditary nonpolyposis colorectal
cancer-associated cancer (colorectal cancer, endometrial, sto-
mach, ovary, ureter/pelvis renal, brain, small bowel, biliary
tract and skin –sebaceous tumors–)
1. One is a first-degree relative of the other two
2. At least two successive generations should be affected
3. At least one cancer case diagnosed before age 50 years
Bethesda criteria (revised 2004)
1. Colorectal cancer diagnosed before age 50 years
2. Presence of synchronous or metachronous colorectal cancer,
or other HNPCC-related cancer* regardless of age
3. Colorectal cancer with MSI-H morphology (characterized by
the presence of tumor infiltrating lymphocytes, mucinous/sig-
net-ring differentiation, peritumoral Crohn’s like lymphocytic
reaction, or medullary growth pattern) before age 60 years
4. Colorectal cancer with one or more first-degree relatives with
colorectal cancer or other HNPCC-related cancer,*one of the
cancers before age 50 years
5. Colorectal cancer with two or more relatives with colorectal
cancer or other HNPCC-related cancer* regardless of age
*Includes colorectal, endometrial, ovarian, gastric, small bowel, urinary tract, bi-
liary tract, pancreas, brain, and sebaceous gland.
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fore considered uninformative unless a mutation has been
previously identified in an affected family member. Nev-
ertheless, genetic testing is considered a standard of care
in the management of hereditary colon cancer.
TREATMENT
Surveillance for colon cancer
Once a high-risk individual is recognized, manage-
ment focuses primarily on strategies for risk reduction.
Colonoscopy and prophylactic colectomy are the primary
strategies to prevent colon cancer or detect it at an early
stage.
The American Gastroenterology Association recom-
mends annual sigmoidoscopy in patients with classic
FAP and at-risk relatives starting at the age of 10-12 yr
(30). Patients with adenomatous polyps on sigmoi-
doscopy should undergo full colonoscopy to establish the
severity of polyposis.
A full colonoscopy is recommended annually in atten-
uated FAP patients starting from age 18-20 years, due to
the tendency of colonic adenomas to be located proxi-
mally (31). It is reasonable to follow these recommenda-
tions in MAP patients beginning at the same age, but per-
forming colonoscopy at 2-yearly intervals (31).
Individuals with Lynch syndrome should be offered
colonoscopy every one to two years, beginning at the age
of 20 to 25 years (age 30 years in families with MSH6
mutations), or ten years younger than the youngest age at
diagnosis in the family (32) whatever comes first, and
then annually after age 40 (33). Evidence of an accelerat-
ed rate of progression from adenoma to carcinoma cou-
pled with the subtle endoscopic appearance of the typical
flat adenomas and cancers in this syndrome serve as jus-
tifications for the short screening interval (34). CRC
screening by means of colonoscopy and polypectomies in
at-risk individuals for Lynch syndrome reduces CRC in-
cidence by 62%, prevents CRC deaths, and decreases
overall mortality by about 65% in Lynch syndrome fami-
lies (35).
Surgical treatment in hereditary colon cancer
syndromes
In polyposis syndromes, surgery is the recommended
approach for cancer prevention. Colectomy remains the
optimal prophylactic treatment for FAP patients, which
has been shown to increase survival by approximately
three decades compared with undiagnosed FAP patients
(36). However, the choice of procedure remains contro-
versial. Surgical options include a total proctocolectomy
(TPC) with permanent ileostomy, a total proctocolectomy
with ileal pouch anal anastomosis (IPAA), or a subtotal
colectomy with ileorectal anastomosis (IRA) (2).
TPC with permanent ileostomy is rarely chosen as a
primary procedure, but it is justified under certain condi-
tions: presence at diagnosis of an invasive cancer involv-
ing the distal rectum, when IPAA or IRA is not technical-
ly feasible because of desmoids, and based on patients
preferences in terms of lifestyle (4).
The key in deciding between an IPAA and an IRA is
the rectal polyp burden and subsequent risk of rectal can-
cer. If at the time of diagnosis, there is diffuse polyposis
in the rectum, an IPAA procedure is recommended. More
difficult to decide is the scenario when there is not much
rectum involved at the time of surgery. The location of
the APC germline mutation was proposed for surgical de-
cision making, but this information is not always avail-
able at the time of surgery, nor does a perfect correlation
between genotype and phenotype exist. Recently, the
presence of fewer than 10 rectal polyps at presentation
has been shown to be a good predictor of a favorable out-
come after IRA (37).
Other factors that should be taken into account are fer-
tility and desmoid development. Studies reported that fer-
tility was significantly reduced after IPAA compared to
IRA in women with FAP (38). Therefore, in young women
who wish to have children, an IPAA should be avoided or
postponed if it is possible (31). In patients with an in-
creased risk of desmoid development (patients with a posi-
tive family history for these lesions or patients with a mu-
tation located distal to codon 1444) a primary IPAA might
be the best option. In these patients the conversion of IRA
to IPAA might be very difficult due to mesenteric desmoid
tumors and shortening of the mesentery (31).
Because functional results are fairly similar for IRA
and IPAA (39) and the estimated cumulative risk of rectal
cancer when the rectum is left is 10% at the age of 50
years and 29% by the age of 60 years (40), IPAA is gen-
erally preferred. However, the risk of cancer after IPAA
procedure is not entirely eliminated. Neoplasia may oc-
cur along the rectal cuff at the site of ileal pouch anasto-
mosis, and the frequency appears to be greater after sta-
pled anastomosis (range, 28% to 31%) than after
mucosectomy and hand-sewn anastomosis (range, 10%
to 14%) (41,42). Therefore, regardless of the procedure,
close lifetime surveillance of the remaining rectum after
IRA every 3-6 months is required, or the ileal pouch and
rectal cuff after IPAA every 6-12 months (31).
There are no guidelines regarding the timing of
surgery. In most cases, surgery is indicated if there are
large numbers of adenomas > 5 mm, including adenomas
showing a high degree of dysplasia. Most patients with
classical FAP undergo surgery between age 15 and 25
years (31).
Special consideration deserves patients with an attenu-
ated polyposis phenotype and a strong family history for
aggressive abdominal desmoid disease. Since abdominal
trauma is associated with desmoids develop, delayed pro-
phylactic colectomy while colonic polyp burden is con-
trolled by polypectomy is preferred (43).
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The high frequency of colorectal cancer observed in
the MYH-associated polyposis syndrome suggests that
prophylactic colectomy may also be indicated. The
choice between an IPAA and an IRA procedure can be
based upon the number of rectal polyps at diagnosis, as in
FAP (31,37).
Prophylactic subtotal colectomy with IRA in Lynch
syndrome patients should be considered in individuals
who are known mutation carriers and have recurrent ade-
nomas with a high degree of dysplasia or a villous growth
pattern or adenomas that are endoscopically unresectable
(27). In known mutation carriers without any colorectal
adenomas, screening colonoscopy appears to be the most
reasonable choice (32). However, prophylactic subtotal
colectomy remains an option for patients who have sig-
nificant anxiety about cancer risk or concern about safety
of repeated colonoscopy or are unable to undergo period-
ic surveillance colonoscopy (27).
For those patients who will undergo surgical resection
of a diagnosed colon cancer, subtotal colectomy instead
of segmental resection is recommended due to the high
risk of metachronous tumors (40% at 10 years) (27,44).
No data are yet available to demonstrate that this surgical
procedure is superior to intensive colonoscopic surveil-
lance after segmental resection, although mathematical
models have suggested an advantage for the more radical
procedure especially in younger individuals with early-
stage cancers (45).
The risk of rectal cancer in Lynch syndrome patients
after subtotal colectomy is estimated at 12% at 12 years,
so annual surveillance of the rectum should be performed
(46).
Chemoprevention of colon cancer
Several studies have demonstrated that regular use of
nonsteroidal anti-inflammatory drugs (NSAIDs) and se-
lective COX-2 inhibitors can reduce polyp number and
size in patients with FAP.
Regression of colorectal adenomas with sulindac (a
nonsteroidal anti-inflamatory drug) has been demonstrat-
ed feasible, reducing the number of polyps to 44% of
base-line values and the diameter of the polyps to 35% of
base-line values after 9 months of treatment, but this ef-
fect was maintained over short follow-up periods (≤ 1
year) (47). Sulindac therapy is recommended in FAP pa-
tients after subtotal colectomy with IRA (48). However,
rectal cancer has developed in patients in whom rectal
polyps were effectively controlled with sulindac (49-51).
In addition, sulindac appears to lack significant benefit in
regressing duodenal adenomas (52) or preventing initial
occurrence of adenomas in APC mutation carriers (pri-
mary prevention) (53). Thus, it cannot be considered as a
reasonable alternative to surgery in FAP patients.
Celecoxib, a selective COX-2 inhibitor, has also
shown a significant reduction (28%) in the number of
colorectal polyps at the dose of 800 mg/day after six
months of treatment (54). The same dose of celecoxib
significantly reduces the number of duodenal polyposis
(by 14.5% in the overall population and 31% in patients
with more than 5% of their duodenal area covered with
polyps at baseline) (55). In addition, rofecoxib has been
demonstrated effective in maintaining the colon free of
polyps in polyposis patients after endoscopic removal of
all visible adenomas (56). However, significant cardio-
vascular side effects associated with these drugs limit
their use as chemopreventive agents.
The efficacy of NSAIDs in Lynch syndrome is un-
known. Biological evidence indicates that Lynch-associ-
ated tumors express lower levels of COX-2, suggesting
that chemoprevention with NSAIDs or COX-2 inhibitors
may be less effective (57). Also, it has been demonstrated
lately that sulindac induces an increase in epithelial cell
proliferation in the proximal colon of subjects with HN-
PCC (58). Since colorectal cancer predominantly arises
in the proximal colon in HNPCC, these results shed
doubts on the potential chemopreventive effects of sulin-
dac in HNPCC.
Extracolonic tumor surveillance
In FAP patients, the cumulative risk (43% at the age of
60 yr and 50% at the age of 70 yr) (59) of developing ad-
vanced duodenal adenomas (Spigelman’s stage IV)
(Table II) supports the importance of routine upper endo-
scopic surveillance. Although only about 5-10% of FAP
patients are estimated to progress to duodenal cancer
(10,11,60), the prognosis after surgery for established tu-
mor is poor (61-63). Moreover, an increase in severity of
duodenal adenomatosis (due to an increasing number and
size of adenomas) with age has been shown (10). There-
fore, the aim of endoscopic surveillance is to identify pa-
tients at greatest risk of duodenal cancer and to intervene
before an invasive tumor develops and when disease is at
a potentially curable stage.
Because nearly two-thirds of duodenal adenomas oc-
cur in the papilla or periampullary region (64) and up
to 12% of duodenal adenomas are indeed microadeno-
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Table II. Spigelman classification for duodenal polyposis
in FAP
Criterion 1 point 2 points 3 points
Polyp number 1-4 5-20 > 20
Polyp size (mm) 1-4 5-10 > 10
Histology Tubular Tubulovillous Villous
Dysplasia Mild* Moderate* Severe**
Stage 0: 0 points; stage I: 1-4 points; stage II: 5-6 points; stage III: 7-8 points;
stage IV: 9-12 points.
*a low degree of dysplasia according to current classification; **a high degree of
dysplasia.
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mas without visible lesions (10), upper endoscopy with
side-viewing endoscopes and systematic biopsies of the
duodenal papilla are essential. Surveillance should be-
gin in the mid 20’s (or 5 years earlier than the youngest
case of advanced duodenal adenomatosis in the family)
and be repeated every 1-3 years depending on polyp
burden.
The management of duodenal polyps remains a chal-
lenge, with different opportunities for endoscopical, sur-
gical and pharmacological therapy. Prophylactic pancre-
aticoduodenectomy, either Whipple’s operation or
pylorus-sparing procedure, is the most hazardous election
with procedural mortality rates estimated around 5%
(65). However, at least two reports of the larger series in-
dicated that pre-operative polyposis staging might under-
estimate disease severity (66,67). Carcinoma was found
in 30 and 50% of the patients undergoing theoretically
prophylactic surgery in those series. Hence, surgical re-
ferral should be considered for the high-risk group
(Spigelman’s stage IV). Rapidly growing lesions and pe-
riampullary adenomas in patients over 35-40 yr of age,
particularly if there is a family history of duodenal cancer
should also be referred to surgery (67).
Endoscopic management of duodenal adenomatosis
attracts increasing interest. Return to normal histology
(34%) and downgrading in the Spigelman stage III and
IV in either periampullary or extra-ampullary adenomas
have been reported (68,69). However, only longer-term
follow up will determine whether repeated endoscopic
intervention, either alone or in combination with pharma-
cological therapy, may be offer to selected patients.
The prevalence of thyroid cancer (12%), particularly
in female FAP patients, might be higher than previously
considered. Screening with thyroid ultrasound allows de-
tection of small tumors (12), and annual thyroid ultra-
sound starting at age 18 years should be considered.
Thus far, there are no data demonstrating an effect of
endometrial cancer screening upon morbidity and mortal-
ity in women with Lynch syndrome. However, because
the lifetime risk of endometrial cancer is high, considera-
tion of screening in this high-risk population is recom-
mended. Thus, women at risk should be offered annual
endometrial biopsy and annual transvaginal ultrasound
starting at age 30 to 35 years. In addition, this procedure
may be useful in ovarian cancer screening (32). Prophy-
lactic total abdominal hysterectomy with bilateral salpin-
go-oopherectomy (TAHBSO) should be considered in
patients whose childbearing is complete, especially when
there is endometrial cancer in the family (70). The opti-
mal timing of prophylactic surgery is unclear. Some ex-
perts recommend that TAHBSO should be offered to pa-
tients who have Lynch syndrome and will undergo
surgery for CRC resection (32).
There are no data to support additional surveillance in
Lynch syndrome patients, and specific recommendations
are typically based upon the specific family history of
cancer. Lately, the European group has recommended
gastric cancer surveillance in Lynch syndrome families in
countries with a high incidence of such tumor (27).
Moreover, urinalysis, urine cytology, upper gastrointesti-
nal tract endoscopy and abdominal ultrasound have been
advocated by several experts (32).
Family counseling
Diagnosis of a genetic disorder has implications for
many family members, especially in inherited cancer
syndromes. Genetic testing may reduce cancer risk
through effective medical procedures. Once a pathogenic
mutation has been identified in an affected individual, at-
risk relatives can be tested for that same mutation with
virtually 100% accuracy.
FAP and Lynch syndrome are inherited in an autoso-
mal dominant manner. Therefore, first degree relatives
are at 50% risk of inheriting the mutation. The majority
of individuals have inherited the mutation from a parent.
However, if clinical and family history cannot identify
from which parent the proband inherited the alteration,
molecular genetic testing should be offered to both par-
ents to determine which one has the gene mutation. Sib-
lings and offspring of a proband should be offered genet-
ic testing.
Due to the autosomal recessive pattern of inheritance
in MAP syndrome, proband siblings will have a 25% risk
of also having biallelic mutations and thus they should be
considered for genetic testing. Because children of the
proband are obligatory carriers, it may be reasonable to
screen partner’s proband to determine the risk of MAP in
any future children (71).
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